Rapport Therapeutics, Inc.
RAPPNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for RAPP. That does not mean none is planned.
Get an email about RAPP's next catalysts
Track Rapport Therapeutics (RAPP) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 5 past
No catalysts found.
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
RAP-219 | Phase 3 | Focal Onset Seizures | - | - |
Frequently asked questions
What is in Rapport Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Rapport Therapeutics, Inc.'s (RAPP) pipeline across Phase 3. Its lead program is RAP-219 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Rapport Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Rapport Therapeutics, Inc. (RAPP) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track RAPP biotech catalysts?→
Add RAPP to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Rapport Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.